Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 19, 2025
Transactions
73
Purchases
0
Sales
73
Purchase value
$0.00
Sale value
$76.47M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Benjamin HohlCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Oct 21, 2026Period of report Oct 19, 20260001882764-26-000009
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 19, 2026
Common StockF1F3F2
6,018
$38.4755
$231.55K
38,000
Direct
Filing footnotes · 4
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Filed Oct 21, 2026Period of report Oct 19, 20260001701247-26-000014
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
J. Scott GarlandDirector
4
Filed Oct 5, 2026Period of report Oct 1, 20260001533228-26-000009
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 1, 2026
Common StockF1
13,000
$46.6707
$606.72K
0
Direct
Benjamin HohlCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Sep 21, 2026Period of report Sep 17, 20260001882764-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Sep 21, 2026Period of report Sep 17, 20260001701247-26-000013
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Benjamin HohlCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Aug 19, 2026Period of report Aug 17, 20260001882764-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Aug 19, 2026Period of report Aug 17, 20260001701247-26-000012
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Mika K DerynckDirector
4Rule 10b5-1 plan disclosed
Filed Aug 6, 2026Period of report Aug 4, 20260001865125-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Benjamin HohlCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jul 21, 2026Period of report Jul 17, 20260001882764-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jul 21, 2026Period of report Jul 17, 20260001701247-26-000011
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Lori Anne KunkelDirector
4Rule 10b5-1 plan disclosed
Filed Jul 8, 2026Period of report Jul 6, 20260001536368-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Orbimed Advisors LLC10% owner
OrbiMed Capital GP VII LLC10% owner
OrbiMed Genesis GP LLC10% owner
4
Filed Jun 24, 2026Period of report Jun 22, 20260000947871-26-000653
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 22, 2026
Common StockF1
Benjamin HohlCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jun 22, 2026Period of report Jun 17, 20260001882764-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jun 22, 2026Period of report Jun 17, 20260001701247-26-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Orbimed Advisors LLC10% owner
OrbiMed Capital GP VII LLC10% owner
OrbiMed Genesis GP LLC10% owner
4
Filed Jun 17, 2026Period of report Jun 15, 20260000947871-26-000637
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 15, 2026
Common StockF1
Lori Anne KunkelDirector
4Rule 10b5-1 plan disclosed
Filed Jun 9, 2026Period of report Jun 5, 20260001536368-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed May 20, 2026Period of report May 18, 20260001701247-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 21, 2026Period of report Apr 17, 20260001701247-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Mar 27, 2026Period of report Mar 25, 20260001701247-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Mar 19, 2026Period of report Mar 17, 20260001701247-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Mar 11, 2026Period of report Mar 9, 20260001701247-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Benjamin HohlCHIEF FINANCIAL OFFICER
4
Filed Mar 10, 2026Period of report Mar 6, 20260001882764-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 6, 2026
Common StockF1F2
10,000
$29.5839
$295.84K
51,000
Helen Louise CollinsCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 19, 2026Period of report Feb 17, 20260001701247-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Feb 19, 2026Period of report Feb 17, 20260001584759-26-000009
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 10, 2026Period of report Feb 6, 20260001967150-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001967150-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001584759-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Anish PatelCHIEF OPERATING OFFICER
4Rule 10b5-1 plan disclosed
Filed Jan 13, 2026Period of report Jan 9, 20260001967163-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER
4Rule 10b5-1 plan disclosed
Filed Jan 12, 2026Period of report Jan 8, 20260001967150-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Jan 12, 2026Period of report Jan 8, 20260001584759-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 23, 2025Period of report Dec 19, 20250001967150-25-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Anish PatelCHIEF OPERATING OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001967163-25-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER
4Rule 10b5-1 plan disclosed
Filed Nov 21, 2025Period of report Nov 19, 20250001967150-25-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
Oct 19, 2026
Common StockF1F3F4
5,000
$38.4684
$192.34K
25,000
Direct
Filing footnotes · 5
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $37.785 to $38.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F5All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1This transaction was executed in multiple trades at prices ranging from $46.62 to $46.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2The option, originally for 59,372 shares, vests as to 1/36th of the shares on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F7All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2This transaction was executed in multiple trades at prices ranging from $57.895 to $58.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F4This transaction was executed in multiple trades at prices ranging from $58.945 to $59.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $57.895 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $58.985 to $59.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F6All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025.
F2This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3778. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $50.765 to $51.7481. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $51.77 to $52.7695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6This transaction was executed in multiple trades at prices ranging from $52.77 to $53.7685. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7This transaction was executed in multiple trades at prices ranging from $53.78 to $53.9781. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3565. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $50.85 to $51.8305. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $51.8711 to $52.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6This transaction was executed in multiple trades at prices ranging from $52.8741 to $53.8708. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7This transaction was executed in multiple trades at prices ranging from $53.8793 to $53.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F9All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
F2This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F1These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
F2These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F3This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $42.295 to $43.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $43.3342 to $44.3142. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $44.3548 to $44.945. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
F2These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F3This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons or Gupta is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
F2This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person .
F4This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $27.40 to $28.2278. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1This transaction was executed in multiple trades at prices ranging from $29.43 to $29.7867. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").
F2This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held of record by the Heyman Daigle Trust.
F4The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2This transaction was executed in multiple trades at prices ranging from $25.605 to $26.5928. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F4This transaction was executed in multiple trades at prices ranging from $26.6137 to $27.344. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").
F2This transaction was executed in multiple trades at prices ranging from $25.7133 to $26.7111. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held of record by the Heyman Daigle Trust.
F4This transaction was executed in multiple trades at prices ranging from $26.725 to $27.3454. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
F2This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Patel / Dong Family Trust.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F4This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by RAHD Capital LLC, for which the Reporting Person serves as a managing member.
F2The shares are held of record by RAHD Capital LLC.
F3The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").
F4This transaction was executed in multiple trades at prices ranging from $25.00 to $25.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5The shares are held of record by the Heyman Daigle Trust.
F6This transaction was executed in multiple trades at prices ranging from $25.00 to $25.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2This transaction was executed in multiple trades at prices ranging from $16.605 to $17.115. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
F2This transaction was executed in multiple trades at prices ranging from $20.51 to $21.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Patel / Dong Family Trust.
F4This transaction was executed in multiple trades at prices ranging from $21.51 to $22.055. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2This transaction was executed in multiple trades at prices ranging from $22.035 to $23.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F4This transaction was executed in multiple trades at prices ranging from $23.045 to $23.165. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.